2-methyl-butyl chloroformate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 2-methyl-butyl chloroformate
• 英文别名: 1-chlorocarbonyloxy-2-methyl-butane；carbonochloridic acid 2-methyl-butyl ester；2-Methylbutyl chloroformate；2-methylbutyl carbonochloridate
• 化学式: C₆H₁₁ClO₂
• 分子量: 150.605
• InChiKey: MQNLOOJFAVAAKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-butyl chloroformate 在 potassium carbonate 、 sodium hydroxide 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 5'-脱氧-5-氟-N-[(2-甲基丁氧基)羰基]胞苷
  参考文献：
  名称：

  Synthesis and biological activity evaluation of cytidine-5′-deoxy-5-fluoro-N-[(alkoxy/aryloxy)] carbonyl-cyclic 2′,3′-carbonates

  摘要：

  Capecitabine, an oral prodrug of 5-FU was developed to improve the tumor selectivity and tolerability. To enhance the efficacy of capacitabine, a series of 5'-deoxy-5-fluorocytidine derivatives 5a-e were synthesized. In the present study, we investigated antitumor activity of 5'-deoxy-5-fluorocytidine derivatives both in vivo and in vitro methods. Title compounds were non-mutagenic to Salmonella typhimurium tester strain in Ames test. Compounds 5d and 5e are potent to inhibit the proliferation of NCI-69, PZ-HPV-7, MCF-7 and HeLa cells in MU assay. In particular, 5d and 5e showed potent antitumor activities against L1210 leukemia cell line. Collectively, these findings suggest that 5d and 5e are more potent anti-cancer compounds than capecitabine. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2012.06.023
• 作为产物：
  描述：

  2-甲基丁醇 、 三光气 在 dioxide titanium 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 2-methyl-butyl chloroformate
  参考文献：
  名称：

  一种卡培他滨杂质F的快捷制备方法

  摘要：

  本发明涉及一种卡培他滨杂质F的快捷制备方法，它包括以下步骤：（a）向反应容器中加入2‑甲基‑1‑丁醇、四氢呋喃、三乙胺和纳米二氧化钛，氮气置换后降温至≤0℃，滴加三光气的四氢呋喃溶液，在紫外光的照射下进行反应；过滤得滤液，旋干得第一混合物；（b）向另一反应容器中加入碳酸钾、2',3'‑二‑O‑乙酰基‑5'‑脱氧‑5‑氟胞苷和丙酮，氮气置换后，滴加第一混合物的丙酮溶液进行反应，过滤得第二混合物的反应液；（c）将第二混合物的反应液降温至≤‑10℃，调节pH至碱性以进行反应。这样能够促进2‑甲基‑1‑丁醇的氧化、酰基化，从而在保证纯度的基础下缩短反应时间，以简化工艺步骤。

  公开号：

  CN109485685A

文献信息

• CARBONIC ACID ESTER AND MAGNETIC RECORDING MEDIUM
  申请人：IMAKUNI Akira

  公开号：US20080241599A1

  公开（公告）日：2008-10-02

  A carbonic acid ester is provided that is represented by the formula below and has a melting point of no greater than 0° C. (In the formula, R 1 and R 2 independently denote a saturated hydrocarbon group, R 1 is a branched chain, and R 2 is a straight or branched chain). There is also provided a magnetic recording medium that includes a non-magnetic support and, above the support, at least one magnetic layer including a ferromagnetic powder dispersed in a binder, the magnetic layer including the carbonic acid ester. Furthermore, there is provided a magnetic recording medium including a support and, above the support, a non-magnetic layer including a non-magnetic powder dispersed in a binder, and above the non-magnetic layer, at least one magnetic layer including a ferromagnetic powder dispersed in a binder, the non-magnetic layer and/or the magnetic layer including the carbonic acid ester.

  提供一种碳酸酯，其化学式如下，并且其熔点不大于0°C。（在化学式中，R1和R2分别表示饱和碳氢基团，R1是支链，R2是直链或支链）。还提供了一种磁记录介质，包括非磁性支撑物，在支撑物上方至少有一层包括铁磁粉末分散在粘合剂中的磁性层，该磁性层包括碳酸酯。此外，还提供了一种磁记录介质，包括支撑物，在支撑物上方有一层包括非磁性粉末分散在粘合剂中的非磁性层，以及在非磁性层上方，至少有一层包括铁磁粉末分散在粘合剂中的磁性层，其中非磁性层和/或磁性层包括碳酸酯。
• Process for the preparation of capecitabine
  申请人：MacDonald Peter Lindsay

  公开号：US20090209754A1

  公开（公告）日：2009-08-20

  The present application relates to an improved process for the preparation of capecitabine.

  本申请涉及一种改进的卡培他滨制备过程。
• beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF
  申请人：Iriyama Yusuke

  公开号：US20120322995A1

  公开（公告）日：2012-12-20

  The invention provides a process for producing a β-dihydrofuran derivative represented by formula (1) or a β-tetrahydrofuran derivative represented by formula (4), characterized in that the process includes causing a dialkyl dicarbonate, a diaralkyl dicarbonate, or a halide to act on a diol compound represented by formula (2) or (3). The invention also provides a process for producing 4′-ethynyl-2′,3′-didehydro-3′-deoxythymidine or an analog thereof, the process including glycosylation and deprotection.

  该发明提供了一种生产由式（1）表示的β-二氢呋喃衍生物或由式（4）表示的β-四氢呋喃衍生物的过程，其特征在于该过程包括使二烷基二碳酸酯、二芳基二碳酸酯或卤化物作用于由式（2）或（3）表示的二醇化合物。该发明还提供了一种生产4'-乙炔基-2',3'-二去氢-3'-脱氧胸苷或其类似物的过程，包括糖基化和去保护。
• TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
  申请人：Li Song

  公开号：US20090298832A1

  公开（公告）日：2009-12-03

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及公式（I）的2,4,5-三取代噻唑化合物或所有可能的异构体、前药、药用盐、溶剂合物或水合物，用于抑制血浆PLTP活性和/或血浆CETP活性，其中取代基如规范中定义；一种用于制备公式（I）化合物的方法；包括公式（I）化合物的药物组合物以及其用于制备治疗和/或预防与哺乳动物体内增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途，如动脉粥样硬化、心血管疾病和周围血管疾病等。
• 一种高产率卡培他滨杂质F的制备方法
  申请人：河南福萌商贸有限公司

  公开号：CN109320563A

  公开（公告）日：2019-02-12

  本发明涉及一种高产率卡培他滨杂质F的制备方法，它包括以下步骤：（a）向反应容器中加入2‑甲基‑1‑丁醇、四氢呋喃和三乙胺，氮气置换后降温至≤0℃，滴加三光气的四氢呋喃溶液，升温反应；过滤得滤液，旋干得第一混合物；（b）向另一反应容器中加入碳酸钾、2',3'‑二‑O‑乙酰基‑5'‑脱氧‑5‑氟胞苷和丙酮，氮气置换后，滴加第一混合物的丙酮溶液进行反应，过滤得第二混合物的反应液；（c）将第二混合物的反应液降温至≤‑10℃，调节pH至碱性以进行反应；随后调节至中性，旋干丙酮，水相用乙酸乙酯萃取多次，合并有机相，干燥后旋干，经柱层析即可。使得获得的产品具有纯度高、产率高的优点。